Details of the Drug Reposition

General Information of This Drug (ID: DMNFADH)

Drug Name
APR-246   DMNFADH
Synonyms Eprenetapopt
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ovarian cancer DISZJHAP 2C73 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric adenocarcinoma DISWWLTC 2B72 Phase 1/2 [2]
Bladder cancer DISUHNM0 2C94 Phase 1/2 [2]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1 [1]
Esophageal cancer DISGB2VN 2B70 Phase 1 [1]
------------------------------------------------------------------------------------
1 Preclinical Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Preclinical [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030246)